Lifileucel TIL Cell Monotherapy in Patients With Advanced Melanoma After Progression on Immune Checkpoint Inhibitors and Targeted Therapy: Pooled Analysis of Consecutive Cohorts (C-144-01 Study)

Amod Sarnaik, MD, reviews data from a study presented at The Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting on lifileucel tumor-infiltrating lymphocyte [TIL] monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapy.

Related Videos
Sapna Patel, BA, MD
Expert on CSCC
Experts on CSCC
Expert on urothelial carcinoma
Anna C. Pavlick, DO
Expert on prostate cancer
Anna C. Pavlick, DO
Experts on solid tumors
Experts on solid tumors
Carlo Contreras, MD, a surgical oncologist for Skin and Soft Tissue Cancers, a member of the Translational Therapeutics Program, medical director of Ambulatory Services at The Ohio State University Comprehensive Cancer Center (OSUCCC)–James, and an associate professor in the Division of Surgical Oncology at The Ohio State University
Related Content

Nivolumab Plus Relatlimab Induces Durable Responses in Advanced Melanoma

March 16th 2023

CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice

March 6th 2023

FDA Approval Sought for Adjuvant Nivolumab for Completely Resected Stage IIB/C Melanoma

February 28th 2023

FDA Approval Insights: Relatlimab Plus Nivolumab in Melanoma

May 2nd 2022

Intermittent Dosing Schedule of MDM2 Inhibitor Appears Tolerable in Advanced Cancers

February 8th 2023

Launch of AMBLor Test Enables Risk Stratification in Early-Stage Melanoma

February 7th 2023

Nivolumab Plus Relatlimab Induces Durable Responses in Advanced Melanoma

March 16th 2023

CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice

March 6th 2023

FDA Approval Sought for Adjuvant Nivolumab for Completely Resected Stage IIB/C Melanoma

February 28th 2023

FDA Approval Insights: Relatlimab Plus Nivolumab in Melanoma

May 2nd 2022

Intermittent Dosing Schedule of MDM2 Inhibitor Appears Tolerable in Advanced Cancers

February 8th 2023

Launch of AMBLor Test Enables Risk Stratification in Early-Stage Melanoma

February 7th 2023

Nivolumab Plus Relatlimab Induces Durable Responses in Advanced Melanoma

March 16th 2023

CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice

March 6th 2023

FDA Approval Sought for Adjuvant Nivolumab for Completely Resected Stage IIB/C Melanoma

February 28th 2023

FDA Approval Insights: Relatlimab Plus Nivolumab in Melanoma

May 2nd 2022

Intermittent Dosing Schedule of MDM2 Inhibitor Appears Tolerable in Advanced Cancers

February 8th 2023

Launch of AMBLor Test Enables Risk Stratification in Early-Stage Melanoma

February 7th 2023